Fungal Defenses and Drug Resistance Evolve Across Farms, Hospitals, and the Environment

A sweeping new review published in IMA Fungus argues that antifungal resistance cannot be understood by studying hospitals, farms, and natural ecosystems in isolation. The authors, working within the One Health paradigm that links human, animal, plant, and environmental health, contend that the evolutionary dynamics of fungal defense mechanisms operate across ecosystem boundaries, with resistance emerging in one domain directly reshaping the resistance landscape in others. Their central example is stark: the agricultural use of azole fungicides has been directly linked to the emergence of clinically resistant strains of Aspergillus fumigatus, a mold that can cause deadly lung infections in vulnerable patients. Human activity, in other words, is applying evolutionary pressure that crosses from crop fields into intensive care units.

To build this synthesis, the review draws a careful conceptual line between two ideas that are often conflated. Fungal defense mechanisms are the broad adaptive traits that protect fungi from environmental stressors, host immunity, and competition with other microbes. Antimicrobial resistance, by contrast, refers specifically to the ability to tolerate or neutralize therapeutic antifungal drugs. Much of the clinical resistance problem is built upon components of a pre-existing defensive repertoire, but not every defense mechanism confers drug resistance. This framework allows researchers to trace how basal fungal defenses are co-opted and refined under drug selection, eventually becoming stable, heritable resistance that undermines medicine and agriculture alike.

The molecular machinery behind resistance is now well mapped. Fungal cell walls, built from chitin, glucans, and proteins, form the first line of defense and a prime drug target; species with low beta-glucan content, such as the Mucorales, are naturally resistant to echinocandin drugs. Efflux pumps, membrane transporters of the ABC and major facilitator superfamilies, actively expel drugs from cells and are a dominant mechanism in Candida albicans and Nakaseomyces glabratus. Genomic plasticity adds further fuel: aneuploidy and gene amplification, such as amplification of the ERG11 target gene, elevate resistance in Candida species. Biofilms act as physical shields that limit drug penetration, while secreted aspartic proteases degrade host antimicrobial peptides and support biofilm stability, blurring the line between virulence and resistance.

The clinical stakes are severe. Candidozyma auris, formerly Candida auris, has emerged as a multidrug-resistant pathogen with some isolates resistant to multiple antifungal classes, and the World Health Organization has placed both C. auris and A. fumigatus on its list of critical priority pathogens. Cryptococcus neoformans can develop fluconazole resistance during prolonged therapy, complicating the management of cryptococcal meningitis, while echinocandin resistance in N. glabratus is tied to mutations in fks genes. Estimates cited in the review suggest more than 150 million fungal infections occur globally each year, contributing to millions of deaths. Resistant infections translate into longer hospital stays, higher costs, and elevated mortality, particularly among immunocompromised patients whose treatment options are already narrow.

Perhaps the most striking section of the review concerns horizontal gene transfer, a process once considered rare in eukaryotes but now recognized as a powerful engine of fungal adaptation. The canonical example is ToxA, a gene encoding a host-selective necrotrophic effector that triggers programmed cell death in wheat carrying the susceptibility gene Tsn1. ToxA has moved between fungal species via a 14-kilobase type II DNA transposon called ToxhAT, itself embedded within larger mobile elements dubbed Starship transposons, which capture and mobilize gene clusters across genomes. In A. fumigatus, Starship transposons mobilize gene clusters encoding both biofilm-associated virulence factors and antifungal tolerance. Horizontal transfer of resistance plasmids and transposons has also been documented in clinical fungi, including Candida species and A. fumigatus, disseminating triazole resistance across species and environments.

Hybridization compounds the problem by creating entirely novel genetic backgrounds. Crosses between Cryptococcus neoformans and Cryptococcus deneoformans have generated lineages with enhanced environmental survival and clinical persistence, while aneuploidy and loss of heterozygosity give hybrids fitness advantages over their parents. In agriculture, hybridization in mildew pathogens affecting wheat and rye has produced strains capable of overcoming host resistance, and quantitative trait locus mapping in hybrid Saccharomyces has identified genomic regions associated with resistance to fluconazole, micafungin, and flucytosine. The review argues that these processes blur the distinction between general adaptability and targeted drug resistance, since a single hybridization event can amplify thermotolerance, stress adaptation, and drug efflux simultaneously.

The TR34/L98H mutation in the cyp51A gene of A. fumigatus has become the emblem of cross-domain resistance. Characterized by a 34-base-pair tandem repeat in the promoter region and a leucine-to-histidine substitution, this alteration confers broad resistance to medical azoles. First detected in both environmental and clinical isolates in the Netherlands, it has since spread across parts of Asia, Africa, and the Americas. Closely related genotypes have been found in fungicide-treated soils and in patient lung samples, and resistant spores have been recovered from hospital air, agricultural soils, and compost. Population genetic studies indicate that environmentally driven resistance alleles such as TR34/L98H and TR46/Y121F/T289A have spread internationally through selective sweeps initiated by agricultural fungicide pressure, with identical genotypes documented in China, Portugal, and the United States.

Detection and management tools are evolving in response. Digital PCR can now quantify low-frequency resistance alleles, next-generation sequencing characterizes resistance genes directly from clinical samples, and CRISPR-based systems, including CRISPR-Cas13 diagnostics and a CRISPR activation platform in C. albicans, are opening new avenues for studying and detecting resistance in real time. Artificial intelligence is being applied to analyze resistance patterns and predict emerging trends. On the management side, antifungal stewardship programs have reduced antifungal consumption and improved prescribing appropriateness without increasing mortality, though a US review found they did not significantly affect mortality or length of stay, underscoring that stewardship alone is insufficient. Combination therapy, therapeutic drug monitoring, and diagnostics-driven de-escalation all form part of a broader response.

The review’s authors are candid about the limits of current knowledge. Research has disproportionately focused on economically important genera such as Candida, Aspergillus, and Cryptococcus, while early-diverging and environmentally dominant lineages are systematically missed by standard metabarcoding workflows. Laboratory conditions strip away the competition, fluctuating resources, and microbial co-evolution that drive resistance in nature, and phylogenetic uncertainty, annotation gaps, and uneven global sampling all distort evolutionary inference. There is also genuine scientific debate over tempo: some researchers argue that efflux systems and stress responses predate modern antifungal use and represent standing variation, while others contend that intensive azole exposure has accelerated resistance through selective sweeps and gene flow between environmental and clinical populations.

The proposed way forward is deliberately structural. The authors call for One Health Fungal Resistance Consortia that would unify clinical, veterinary, agricultural, and environmental efforts through shared biorepositories, interoperable genomic databases with harmonized metadata, and cross-domain validation of diagnostics such as CRISPR-based assays. They envision joint evolutionary risk assessment, in which interdisciplinary teams model how fungicide deployment in specific crops may influence regional resistance patterns over five-year horizons, including downstream impacts on nearby healthcare facilities. With climate change potentially expanding the geographic range of thermotolerant, drug-resistant species like C. auris, and the antifungal drug pipeline remaining thin, the review’s conclusion is unambiguous: because resistant fungi succeed by coupling defense, adaptation, and resistance across environments, containment strategies must be equally integrated, linking scientific innovation with coordinated governance to protect public health, food systems, and ecosystems together.

Subject of Research: Evolution of fungal defense mechanisms and antifungal resistance across clinical, agricultural, and environmental domains

Article Title: Interconnected worlds: a comprehensive review of fungal defenses, antimicrobial resistance, and their evolutionary dynamics

Article References: Sui, Y., Nizamani, M. M., Tarafder, E., Zhang, H.-L., Zhang, Q., Acharya, K., Sarkar, J., Muhae-Ud-Din, G., & Wang, Y. (2026). Interconnected worlds: a comprehensive review of fungal defenses, antimicrobial resistance, and their evolutionary dynamics. IMA Fungus, 17, Article e171995. https://doi.org/10.3897/imafungus.17.171995

Image Credits: AI Generated

DOI: 10.3897/imafungus.17.171995

Keywords: antifungal resistance, One Health, Aspergillus fumigatus, horizontal gene transfer, azole fungicides, Candida auris, efflux pumps, hybridization, TR34/L98H, cell wall integrity, biofilms, antimicrobial stewardship